Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

October 21, 2019

Apellis Stopping Development of APL-2 for Lupus Nephritis After Completion of Phase 2 Trial

News

Apellis Pharmaceuticals has decided to stop the development of an experimental therapy known as APL-2 for lupus nephritis and primary membranous nephropathy after the completion of an ongoing Phase ... Read more

October 7, 2019October 21, 2019

‘Lupus Low Disease Activity State’ Protects Patients Against Flares, Organ Damage, Study Suggests

News

Patients with systemic lupus erythematosus (SLE) who attain a low disease state have a lower risk of subsequent disease flares and accumulated organ damage, making this state a potential ... Read more

September 13, 2019September 13, 2019

CARRA Granted $2.4M for Research Efforts to Determine Lifetime Outcomes of Children and Adolescents with Lupus

News

The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has been awarded a three-year $2.4-million grant from the U.S. Centers for Disease Control and Prevention (CDC), which will help efforts ... Read more

July 31, 2019August 26, 2019

Progentec Granted $1.7M to Validate Measure of SLE Disease Activity

News

Progentec, a company developing new diagnostic technologies for chronic conditions, has been awarded $1.7 million to validate its blood biomarker test as an accurate tool for measuring disease activity ... Read more

July 29, 2019

‘Lupus Low Disease Activity State’ Linked to Reduced Healthcare Costs, Study Confirms

News

Attaining a low disease state — deemed Lupus Low Disease Activity State or LLDAS — has become a major goal for treatment for people with systemic lupus erythematosus. Researchers ... Read more

July 8, 2019

Lupus Research Alliance, Bristol-Myers Join to Advance Phase 2 Study of Oral Treatment for Lupus Nephritis

News

The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics have expanded a collaboration with Bristol-Myers Squibb to help assess the company’s investigational agent BMS-986165 as a possible treatment for lupus ... Read more

June 14, 2019

KZR-616 Shows Early Promise in Treatment of Active SLE

News

KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were ... Read more

May 8, 2019

Mallinckrodt Completes Enrollment in Phase 4 Trial Testing Acthar Gel in SLE Patients

News

Mallinckrodt Pharmaceuticals has completed enrollment for its Phase 4 clinical trial evaluating the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) in patients with persistently active systemic lupus erythematosus (SLE). The company expects the ... Read more

March 25, 2019

Equillium Plans to Open Phase 1 Trial of EQ001 in Lupus Nephritis Patients Toward End of Year

News

Equillium announced that it is planning to test EQ001, its monoclonal antibody, in a Phase 1b trial as a potential therapy for patients with refractory lupus nephritis, among the most frequent and ... Read more

March 11, 2019

Lupus Therapeutics, Takeda Launch Phase 1 Trial of TAK-079 for Moderate to Severe SLE

News

The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial testing Takeda’s investigational antibody TAK-079 for the treatment of systemic lupus erythematosus (SLE) ... Read more

This is a short description about myself and what this site is about. I hope you enjoy being here!

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Apellis Stopping Development of APL-2 for Lupus Nephritis After Completion of Phase 2 Trial

‘Lupus Low Disease Activity State’ Protects Patients Against Flares, Organ Damage, Study Suggests

CARRA Granted $2.4M for Research Efforts to Determine Lifetime Outcomes of Children and Adolescents with Lupus

Progentec Granted $1.7M to Validate Measure of SLE Disease Activity

‘Lupus Low Disease Activity State’ Linked to Reduced Healthcare Costs, Study Confirms

Lupus Research Alliance, Bristol-Myers Join to Advance Phase 2 Study of Oral Treatment for Lupus Nephritis

KZR-616 Shows Early Promise in Treatment of Active SLE

Mallinckrodt Completes Enrollment in Phase 4 Trial Testing Acthar Gel in SLE Patients

Equillium Plans to Open Phase 1 Trial of EQ001 in Lupus Nephritis Patients Toward End of Year

Lupus Therapeutics, Takeda Launch Phase 1 Trial of TAK-079 for Moderate to Severe SLE

Pin It on Pinterest